FindTrial
Sign In

ALKS 8700

DRUG2 trials

Sponsors

Biogen

Conditions

Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Phase 3

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
CompletedNCT02634307
BiogenMultiple Sclerosis
Start: 2015-12-10End: 2021-11-11Updated: 2022-07-26
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
CompletedNCT03093324
BiogenRelapsing Remitting Multiple Sclerosis
Start: 2017-03-15End: 2019-06-27Updated: 2020-07-14

Related Papers

Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis
Journal of Comparative Effectiveness Research2025-09-12
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.
2024-09-303 citations
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons
Journal of Comparative Effectiveness Research2024-08-192 citations
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.
2024-06-271 citations
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.
2024-06-151 citations
Diroximel fumarate pregnancy outcomes in EVOLVE-MS-1 and prospective MS pregnancy exposure registry study design
2023-11-01
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis.
2023-05-084 citations
Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 after Re-baselining in the Phase 3 EVOLVE-MS-1 Study (P8-3.001)
Neurology2023-04-25
Diroximel Fumarate Pregnancy Outcomes in EVOLVE-MS-1 and Study Design of Diroximel Fumarate Prospective MS Pregnancy Exposure Registry (P9-3.003)
Neurology2023-04-25
Male MS Patients’ Safety, Tolerability and Efficacy Outcomes Do Not Differ from Female Patients Treated with Diroximel Fumarate: EVOLVE-MS-1 Ad-hoc Analysis (P8-3.017)
Neurology2023-04-25
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
2022-02-2425 citations
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
Therapeutic Advances in Neurological Disorders2021-01-0122 citations
Diroximel fumarate and dimethyl fumarate demonstrate early clinical and radiological efficacy in relapsing-remitting multiple sclerosis (1337)
Neurology2020-04-14
Improved Gastrointestinal Tolerability Profile with Diroximel Fumarate Compared to Dimethyl Fumarate in Relapsing MS Patients (994)
Neurology2020-04-14
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
2020-02-0188 citations
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
2019-09-1947 citations
Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study (P3.2-060)
Neurology2019-04-09